Verdiva Bio Advances Obesity Therapy with Once-Weekly Oral GLP-1 Peptide Analog Is the pharmaceutical industry on the brink of a breakthrough in obesity treatment? Verdiva Bio Limited a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, has…
SolasCure Ltd Demonstrates Superior Wound Healing with Aurase Wound Gel Why are chronic wounds a persistent challenge for healthcare systems, and how can new treatments make a difference? SolasCure Ltd, a biotechnology company focused on transforming chronic wound healing, has announced the…
Strategic Partnership Combines Best-in-Class Cell Line Development and GMP Manufacturing Why do biotech companies often face long development cycles and costly delays? NorthX Biologics and Demeetra have formed a strategic collaboration to address these challenges. NorthX Biologics, a leading contract…
ClearNote Health Enhances Early Detection of Pancreatic Cancer with New Avantect® Test Why is early detection of pancreatic cancer so critical? ClearNote Health, a company dedicated to improving early detection for some of the deadliest cancers, has launched an enhanced…
Atara Biotherapeutics Secures Flexibility for Tabelecleucel Development Why is the timing of milestone payments crucial for biotech companies? Atara Biotherapeutics, Inc. a leader in T-cell immunotherapy, has secured an extension on a significant milestone payment, providing the company with more…
Pelage Pharmaceuticals Appoints New Board Member and Promotes Key Executives In the competitive landscape of regenerative medicine, where innovative solutions for hair loss are increasingly in demand, Pelage Pharmaceuticals is making strategic moves to solidify its position. The company, a…
Positive Top-Line Results for Reblozyl in Alpha-Thalassemia Study Is the treatment landscape for alpha-thalassemia about to change? Bristol Myers Squibb has announced positive top-line results from an ongoing, ex-US, Phase 2 registrational study evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia…
Gilead Sciences Seals $7.8 Billion Deal for Arcellx to Boost CAR T-Cell Therapy In the rapidly evolving landscape of cancer immunotherapies, where breakthroughs are crucial for patient outcomes, Gilead Sciences, Inc. has made a significant move. The biopharmaceutical giant has…
AOP Health Emphasizes Collaboration and Patient-Centered Information on Rare Disease Day 2026 Why is the diagnosis and treatment of rare diseases so challenging? AOP Health, a global enterprise group with roots in Austria, is dedicated to addressing this critical issue.…
Science Corp. and Neurosoft Bioelectronics Announce Novel BCI Ecosystem Partnership Science Corporation, the pioneering full-stack neural engineering company focused on restoring and extending life, and Neurosoft Bioelectronics, a neural data company utilizing ultra-soft interfaces to achieve full-cortical coverage powering a foundation…
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting AstraZeneca’sCALQUENCE® in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for…
Element Biosciences Introduces VITARI™, Redefining What High-Throughput Sequencing Makes Possible Element Biosciences Inc. today announced VITARI, the first ever high-throughput benchtop sequencing system capable of delivering a high-quality whole genome at $100. With the introduction of VITARI, Element now offers a…